GLP-1 Thyroid Warning Could Increase Overdiagnosis.

Clinicians should be cautious about overdiagnosis of thyroid cancer when prescribing glucagon-like peptide 1 (GLP-1) drugs, as the US boxed warning about this risk could lead to excess screening. The American Thyroid Association and the US Preventive Services Task Force have both sought to raise awareness about the potential risks of excessive thyroid screening. It is important for clinicians to adhere to guidelines for assessing nodules and to educate patients about the commonality of thyroid nodules and the low likelihood of malignancy. The European Medicines Agency does not include the same warning about thyroid cancer on the labels of GLP-1 drugs as the US does, but ongoing interest in the issue remains. [Extracted from the article]